{"data":{"type":"company_profile_ai","id":165240,"entity_id":"wefunder:company:165240","attributes":{"canonical_url":"https://wefunder.com/eliaz.therapeutics","retrieval_urls":{"canonical":"https://wefunder.com/eliaz.therapeutics","json":"https://wefunder.com/eliaz.therapeutics.json","markdown":"https://wefunder.com/eliaz.therapeutics.md","ai_json":"https://wefunder.com/eliaz.therapeutics.ai.json","ai_text":"https://wefunder.com/eliaz.therapeutics.ai.txt","changelog_json":"https://wefunder.com/eliaz.therapeutics.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-15T05:01:22Z","generated_at":"2026-06-15T10:31:54Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"company":{"id":165240,"entity_id":"wefunder:company:165240","slug":"eliaz.therapeutics","name":"Eliaz Therapeutics","tagline":"Join The Fight Against Sepsis With Our Life-Saving Medical Device: XGal-3®","location":"Santa Rosa, CA","website":"https://www.eliaztherapeutics.com/","total_amount_raised":2509175,"total_investors":1242,"is_funded":true,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 2509175","citation":"https://wefunder.com/eliaz.therapeutics#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-15T05:01:22Z","as_of":"2026-06-15T10:31:54Z","confidence":"high"},"observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-16T05:01:22Z"},{"claim_id":"claim-total-investors","text":"Total investors: 1242","citation":"https://wefunder.com/eliaz.therapeutics#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-15T05:01:22Z","as_of":"2026-06-15T10:31:54Z","confidence":"high"},"observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-16T05:01:22Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 2509175","citation":"https://wefunder.com/eliaz.therapeutics#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-15T05:01:22Z","as_of":"2026-06-15T10:31:54Z","confidence":"high"},"observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-16T05:01:22Z"},{"claim_id":"claim-total-investors","text":"Total investors: 1242","citation":"https://wefunder.com/eliaz.therapeutics#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-15T05:01:22Z","as_of":"2026-06-15T10:31:54Z","confidence":"high"},"observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-16T05:01:22Z"}],"company_claims":{"tagline":"Join The Fight Against Sepsis With Our Life-Saving Medical Device: XGal-3®","story":"Click here to view our pitch deck.Why Eliaz Therapeutics?We’re honored to announce that the FDA has awarded XGal-3® its Breakthrough Device Designation!In the medical world, this designation is highly coveted for many reasons.It validates technologies that address urgent, unmet medical needs. It gives patients timely access to innovative treatments that are highly vetted for safety and effectiveness. And often, it offers hope where there is none.At Eliaz Therapeutics, achieving this milestone represents decades of intensive research coming to fruition. But for our supporters and investors, it represents a tremendous opportunity to help address one of medicine’s most urgent challenges.For over three decades, I've dedicated my life to innovating healthcare solutions that alleviate human suffering. This journey led me to develop Pectosol, a natural Galectin-3 blocker backed by nearly 100 research papers, and build a community of over 300,000 health enthusiasts through my integrative medicine work.The tragic loss of my father to immune dysregulation underlying sepsis ignited a personal mission to combat inflammatory conditions. This led to the creation of XGal-3®, a groundbreaking device designed to halt sepsis progression by targeting Galectin-3, a protein driving the deadly inflammatory process.Our patented technology, supported by 2 prestigious NIH grants and protected by over 60 patents across 34 countries, has the potential to stop sepsis within hours. With our world-class team, we've developed a working prototype and are rapidly advancing towards clinical trials.Back in 2023, ecoNugenics, my previous venture, was successfully acquired by a prestigious private equity company, demonstrating our team's ability to create and realize the value in the healthcare sector.Now, as an investor in Eliaz Therapeutics, you have the opportunity to support a movement—one with the potential to save millions of lives across the world.I sincerely hope you join us in the fight against sepsis.Invest in Eliaz Therapeutics today!Sepsis is a Silent Killer That Claims 11 Million Lives AnnuallySepsis strikes without warning, claiming a life every 2.8 seconds. Despite its devastating impact, it remains largely overlooked in public health discussions. This silent killer turns routine infections into catastrophic bodily responses, leading to rapid organ failure and death.Throughout my career, I've witnessed sepsis devastate countless patients and families. This deadly condition imposes a staggering $62 billion annual burden on the U.S. healthcare system. Current treatments only manage symptoms, neglecting the root cause of sepsis. There is no effective therapy targeting the underlying inflammatory process. Our groundbreaking research at Eliaz Therapeutics aims to change this paradigm, offering hope where none existed before.WHEN GOOD PROTEINS GO ROGUEGalectin-3 is a key driver of sepsis when released into the bloodstream. During sepsis and acute kidney injury (AKI), it triggers a cascade of harmful effects.EFFECTS OF GALECTIN-3 IN SEPSIS AND AKIInflammationDisease progressionOrgan fibrosisIncreased morbidity and mortalityDISEASES ASSOCIATED WITH GALECTIN-3:SepsisKidney diseases (AKI, CKD)Heart diseaseLiver cirrhosisCancer\u0026nbsp;\u0026nbsp;Pulmonary hypertensionStrokeDiabetesAutoimmune diseasesNeuroinflammatory diseasesIntroducing XGal-3®: A New Hope for Sepsis PatientsXGal-3® is a medical device that works like dialysis but with a crucial difference. Using proprietary anti-Galectin-3 antibody traps, it targets and removes Galectin-3 from the bloodstream, potentially halting sepsis progression. By disrupting the pathological cascade, XGal-3® aims to prevent the devastating inflammatory cascade and organ damage, and save lives. This targeted approach tackles the root cause of sepsis, offering new hope for millions.\u0026nbsp;HOW IT WORKS:We connect the patient to XGal-3® using standard IV linesBlood flows through our device and is separated into plasma and cellular componentsXGal-3® removes the harmful Galectin-3 protein from the plasmaThe cleansed blood returns to the patientThe whole process takes just hours, potentially saving the patient's lifeFrom Concept to BreakthroughCreated XGal-3® prototype: A first-of-its-kind sepsis treatmentProtected innovation: 60+ patents in 34 countriesValidated by NIH: Secured 2 research grantsPartnered with Terumo: Global leader in medical apheresis technologyExpanded collaborations: Teamed with a multi-billion dollar diagnostics leaderA $1.97 Trillion Global Market Desperate for InnovationXGal-3® targets a massive $1.97 trillion global market. Our vision is to:Transform the treatment for inflammatory and fibrotic diseasesSave \u0026amp; improve millions of lives worldwideStart with sepsis, then expand to broader applicationsOUR STRATEGY:Target Septic Shock First: Address the urgent unmet need in ICUs, where mortality rates can reach up to 60%Strategic Relationships: Collaborate with global apheresis leader for rapid hospital adoptionMaximize Distribution: Partner with distributors, Group Purchasing Organizations, and hospital networks for widespread adoptionDiversify Revenue: Combine direct sales with strategic licensing opportunitiesExpand Applications: Explore XGAL-3®'s potential in AKI, chronic kidney disease, cancer, and fibrosisOur Team is Led by World-Class Experts from Stanford, Mayo Clinic, and leading Biotech CompaniesI'm incredibly proud of the team we've assembled at Eliaz Therapeutics. We've come together from diverse backgrounds in medicine, research, and business, but we're united by a deep commitment to making a difference in the lives of millions.\u0026nbsp;The Perfect StormWe’re at a critical juncture:\u0026nbsp;COVID-19 highlighted the urgent need for effective sepsis treatmentsMedical community more open to innovative approachesOur working prototype is ready for clinical trialsThe global sepsis treatment market is projected to grow due to aging populations and increasing chronic disease prevalenceTogether, We Can Bring X-Gal-3® to Market and Save Millions of LivesBy investing in Eliaz Therapeutics, you're helping us turn \"goodbye\" into \"welcome home\" for families around the world. Let’s defeat sepsis by making XGal-3®\u0026nbsp;standard equipment in every ICU, saving lives daily.\u0026nbsp;Your investment directly supports:Completing crucial safety and efficacy trials with the FDA to bring XGal-3® to market.Bringing hope to millions facing sepsis and other life-threatening conditionsRevolutionizing the way sepsis and other conditions are treated in hospitals around the world.","quick_facts":["Awarded FDA Breakthrough Device Designation, validating XGal-3®'s potential to save millions","Addressing critical unmet need: first significant advancement in sepsis treatment in 25 years","Targeting a $62B sepsis treatment market in the USA alone, part of a $1.97T global opportunity","Our technology shuts down the sepsis process within hours in large animal studies","Platform technology with potential applications beyond sepsis, including cancer \u0026amp; fibrotic diseases","Over 60 patents across 34 countries securing our innovative technology","Secured 2 prestigious NIH grants, demonstrating scientific merit and potential for commercialization","Strategic partnership with Terumo BCT for development and commercialization of XGal-3® treatment"]},"computed_metrics":{"total_amount_raised":2509175,"total_investors":1242,"team_size":7,"featured_investor_count":4,"faq_count":5,"recent_post_count":10},"quick_facts":[{"claim_id":"claim-fact-1","value":"Awarded FDA Breakthrough Device Designation, validating XGal-3®'s potential to save millions","citation":"https://wefunder.com/eliaz.therapeutics#claim-fact-1","observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-22T05:01:22Z"},{"claim_id":"claim-fact-2","value":"Addressing critical unmet need: first significant advancement in sepsis treatment in 25 years","citation":"https://wefunder.com/eliaz.therapeutics#claim-fact-2","observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-22T05:01:22Z"},{"claim_id":"claim-fact-3","value":"Targeting a $62B sepsis treatment market in the USA alone, part of a $1.97T global opportunity","citation":"https://wefunder.com/eliaz.therapeutics#claim-fact-3","observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-22T05:01:22Z"},{"claim_id":"claim-fact-4","value":"Our technology shuts down the sepsis process within hours in large animal studies","citation":"https://wefunder.com/eliaz.therapeutics#claim-fact-4","observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-22T05:01:22Z"},{"claim_id":"claim-fact-5","value":"Platform technology with potential applications beyond sepsis, including cancer \u0026amp; fibrotic diseases","citation":"https://wefunder.com/eliaz.therapeutics#claim-fact-5","observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-22T05:01:22Z"},{"claim_id":"claim-fact-6","value":"Over 60 patents across 34 countries securing our innovative technology","citation":"https://wefunder.com/eliaz.therapeutics#claim-fact-6","observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-22T05:01:22Z"},{"claim_id":"claim-fact-7","value":"Secured 2 prestigious NIH grants, demonstrating scientific merit and potential for commercialization","citation":"https://wefunder.com/eliaz.therapeutics#claim-fact-7","observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-22T05:01:22Z"},{"claim_id":"claim-fact-8","value":"Strategic partnership with Terumo BCT for development and commercialization of XGal-3® treatment","citation":"https://wefunder.com/eliaz.therapeutics#claim-fact-8","observed_at":"2026-06-15T05:01:22Z","expires_at":"2026-06-22T05:01:22Z"}],"latest_fundraise":{"id":124995,"entity_id":"wefunder:fundraise:124995","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null},"investor_memos":[],"team":[{"id":5219438,"entity_id":"wefunder:company_role:5219438","name":"Dr. Isaac Eliaz (MD)","title":"CEO","role":"founder","profile_url":"https://wefunder.com/isaac.eliaz"},{"id":5222414,"entity_id":"wefunder:company_role:5222414","name":"Anat Stern","title":"COO \u0026 Biz Dev ","role":"employee","profile_url":"https://wefunder.com/anat.stern"},{"id":5222415,"entity_id":"wefunder:company_role:5222415","name":"Milton Goss","title":"CFO","role":"employee"},{"id":5288435,"entity_id":"wefunder:company_role:5288435","name":"Bryan Knipe","title":"Investor relations ","role":"employee","profile_url":"https://wefunder.com/bryan.knipe"},{"id":5464681,"entity_id":"wefunder:company_role:5464681","name":"Susan Alpert ","title":"Senior Regulatory Strategist","role":"employee"},{"id":5222416,"entity_id":"wefunder:company_role:5222416","name":"Glenn M Chertow MD","title":"Director of Medical Affairs","role":"employee"},{"id":5788669,"entity_id":"wefunder:company_role:5788669","name":"Dale Cumming ","title":"VP of Research \u0026 Development ","role":"employee"}],"featured_investors":[{"id":10131,"entity_id":"wefunder:company_investor_profile:10131","name":"Nathan Crane","bio":"Certified professional nutrition coach, bestselling author, award winning natural health researcher, and plant powered athlete.","profile_url":"https://wefunder.com/nathan.crane","endorsement_quote":"An investment in ETI is a no-brainer for me. For someone who cares deeply about the health and well-being of humanity, seeing this powerful new technology come to market that could save millions of people's lives by implementing a non-toxic approach in healthcare is exactly what we need at this time. There's no one better to bring it to the world than Dr. Isaac Eliaz. I believe this investment opportunity will change lives and give a powerful financial opportunity for growth, and I'm very happy to be a part of it."},{"id":10156,"entity_id":"wefunder:company_investor_profile:10156","name":"Russell L. Brand ","bio":"An MIT graduate, entrepreneur, and angel investor, currently serving as Founder and Managing Director of Responsible Solutions Ltd. He focuses on information technology and business consulting","profile_url":"https://wefunder.com/russell.l.brand..1","endorsement_quote":"I have started 3 successful technology companies and invested in many more. The largest investment I have made personally is in Eliaz Therapeutics. Excessive galectin-3 is directly responsible for the majority of in-hospital deaths including those from sepsis, the need for many organ transplants, and massive avoidable suffering. Eliaz Therapeutics is making a blood filter that removes Excessive galectin-3 and can prevent those deaths and much of that suffering. Because it is an external device it can work much more rapidly and safely than a pharmacological intervention and can more quickly receive regulator approval. I see it as one of the most important medical advances of our time."},{"id":10267,"entity_id":"wefunder:company_investor_profile:10267","name":"Glenn Chertow","bio":"Physician-investigator (nephrologist), Stanford University, member of the National Academy of Medicine","profile_url":"https://wefunder.com/glenn.chertow","endorsement_quote":"Sepsis-associated acute kidney injury is a devastating condition for which there are no approved treatments. Higher serum galectin-3 concentrations are associated with adverse outcomes and can be sharply reduced with the extracorporeal adsorption column developed by ETI. A safe, effective treatment for acute kidney injury in critically ill patients could save lives and reduce the burden of maintenance dialysis for patients who survive but whose kidneys fail to recover. I have been waiting more than 30 years for something that could offer hope to patients with sepsis-associated acute kidney injury. I feel compelled to support ETI and the development of this product with a combination of a modest financial investment, and a more considerable investment of my time, effort, and expertise."},{"id":10155,"entity_id":"wefunder:company_investor_profile:10155","name":"Cyrus Khambatta","bio":"PhD in Nutritional Biochemistry. New York Times bestselling author of Mastering Diabetes and co-founder of amlagreen.com","profile_url":"https://wefunder.com/cyrus.khambatta","endorsement_quote":"I’ve been in the world of chronic disease prevention for 20 years and have come across many companies attempting to reduce the burden of many chronic conditions. When I saw ETI’s data in preventing AKI in pre-clinical sepsis models, I was blown away by the effectiveness of treatment with the X-Gal column. The mortality \u0026amp; healthcare costs associated with treating sepsis and sepsis-related injuries is massive, and I’m honoured to be able to help ETI develop a treatment for use in the ICU that’s quick, effective, and life-saving."}],"relationships":[{"source_entity_id":"wefunder:company:165240","relation":"has_team_member","target_entity_id":"wefunder:user:4534864","target_url":"https://wefunder.com/isaac.eliaz"},{"source_entity_id":"wefunder:company:165240","relation":"has_team_member","target_entity_id":"wefunder:user:4472081","target_url":"https://wefunder.com/anat.stern"},{"source_entity_id":"wefunder:company:165240","relation":"has_team_member","target_entity_id":"wefunder:company_role:5222415"},{"source_entity_id":"wefunder:company:165240","relation":"has_team_member","target_entity_id":"wefunder:user:4533147","target_url":"https://wefunder.com/bryan.knipe"},{"source_entity_id":"wefunder:company:165240","relation":"has_team_member","target_entity_id":"wefunder:company_role:5464681"},{"source_entity_id":"wefunder:company:165240","relation":"has_team_member","target_entity_id":"wefunder:company_role:5222416"},{"source_entity_id":"wefunder:company:165240","relation":"has_team_member","target_entity_id":"wefunder:company_role:5788669"},{"source_entity_id":"wefunder:company:165240","relation":"has_featured_investor","target_entity_id":"wefunder:user:4470612","target_url":"https://wefunder.com/nathan.crane"},{"source_entity_id":"wefunder:company:165240","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:13780","target_url":"https://wefunder.com/russell.l.brand..1"},{"source_entity_id":"wefunder:company:165240","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:13890","target_url":"https://wefunder.com/glenn.chertow"},{"source_entity_id":"wefunder:company:165240","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:13778","target_url":"https://wefunder.com/cyrus.khambatta"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:193613","target_url":"https://wefunder.com/feed/193613"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:193499","target_url":"https://wefunder.com/feed/193499"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:192569","target_url":"https://wefunder.com/feed/192569"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:184834","target_url":"https://wefunder.com/feed/184834"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:184278","target_url":"https://wefunder.com/feed/184278"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:184178","target_url":"https://wefunder.com/feed/184178"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:184095","target_url":"https://wefunder.com/feed/184095"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:183843","target_url":"https://wefunder.com/feed/183843"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:183474","target_url":"https://wefunder.com/feed/183474"},{"source_entity_id":"wefunder:company:165240","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:183434","target_url":"https://wefunder.com/feed/183434"},{"source_entity_id":"wefunder:company:165240","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:124995"}],"faq":[{"question":"What do I get if I invest? Is it a stock or share?","answer":"Hi Robert, When you invest in Eliaz Therapeutics via our Wefunder campaign, you receive a Simple Agreement for Future Equity (SAFE). This isn’t a traditional stock or share immediately, but rather a contractual agreement that converts into equity (ownership in the company) during a future fundraising round, such as our upcoming Series A. The benefit of investing in our SAFE now is that if it converts into equity into the future, this will be at the SAFE's valuation cap rather than the valuati..."},{"question":"I completed the investment form as an email option and was given a strong password to continue but after I completed everything the system said it could not accept my investment from my location. Is this investment opportunity only available in the USA? I am a Canadian resident.","answer":"Hi Candace, thank you for your interest in ETI. Certain provinces in Canada can't participate in crowdfunding, at least through WEFunder. There may be alternate ways to do it. What amount were you looking at investing? with gratitude, Isaac"},{"question":"The entity making the investment is a Family Trust. It does not have an EIN. Should I use a social security number","answer":"Hi, I think that SS# is fine , but to make sure I am checking with WeFunder and will get back to you ASAP. Thank you for your support and trust in us. all the best, Isaac"},{"question":"I appreciate that you're submitting your Breakthough Designation Application for the FDA that will fast track some of the process, but what's the regulatory path forward and an anticipated timeline for getting this to patients?","answer":"Thank you, Jason, for your question. We are currently engaged in non GLP and GLP large animal safety studies, while finalizing the column prototype. The anticipated timeline is to file for XGAL-3 clinical trials approval mid 2025 and start the XGAL-3 therapeutic trials early 2026, possibly late 2025. We are already in discussions with a number of excellent medical centers in the USA and outside the USA that are interested in participating. We are also planning to conduct pre-therapeutic diagn..."},{"question":"how is this different / compared to current available solution like Oxiris , we know is holt the process , it might improve the patient temporarily but wont change the outcome of sepsis ...","answer":"XGAL-3 is fundamentally different than Oxiris. OXiris is a blood filtration system used in conjunction with hemodialysis. It is used at a much later stage in the sepsis process, when the patient already has kidney damage/failure that required dialysis in the ICU. It requires high blood flow of 150-200ml/minute. The 90 days outcome of a meta analysis study from 2023 showed that 90-day mortality, ICU and hospital mortality, and length of hospital stay did not improve. XGAL-3 is a highly selecti..."}],"recent_posts":[{"id":193613,"entity_id":"wefunder:feed_item:193613","title":"To Our Investors: This Is Just the Beginning","preview":"To our incredible community of investors and supporters,\u0026nbsp;What you've helped us accomplish is nothing short of remarkable! With your trust and commitment, we’ve raised $3.19M to advance a technology with the potential to fundamentally transform how medicine tackles sepsis.This milestone is only the beginning — and it wouldn’t have been possible without you.With deep appreciation,Isaac and the Team","published_at":"2025-10-01T04:52:08Z","canonical_url":"https://wefunder.com/feed/193613"},{"id":193499,"entity_id":"wefunder:feed_item:193499","title":"My Life’s Work Has Led to This Moment","preview":"With less than 2 days left in our Wefunder campaign, I find myself reflecting on the journey that has brought us here.When I began researching Galectin-3 more than 30 years ago, it was a lonely and uncertain field. The role of this protein in driving inflammation, organ failure, and mortality was largely overlooked. Today, thousands of scientific papers validate what once felt like a solitary pursuit.What began as theory has become a prototype and now, with your support, is on the verge of re...","published_at":"2025-09-28T08:48:56Z","canonical_url":"https://wefunder.com/feed/193499"},{"id":192569,"entity_id":"wefunder:feed_item:192569","title":"Why This Mission Matters","preview":"Every year, sepsis strikes over 49 million people worldwide, including more than 2 million Americans, and causes 11 million deaths. For me, this mission is deeply personal. I lost my father to immune dysregulation underlying sepsis. That experience set me on a path to dedicate my life to understanding Galectin-3 and building therapies aimed at saving lives.With the support of over 1,000 investors, we’re closer than ever to making a difference. Together, we can help bring a new option to patie...","published_at":"2025-09-21T07:33:27Z","canonical_url":"https://wefunder.com/feed/192569"},{"id":184834,"entity_id":"wefunder:feed_item:184834","title":"TRACK RECORD OF SUCCESS - From ecoNugenics to Eliaz Therapeutics","preview":"To our valued Wefunder community,In 2023, a leading private equity firm acquired my previous venture, ecoNugenics, after I had spent three decades building a company that helped hundreds of thousands of patients worldwide.At ecoNugenics, we achieved something remarkable: growing from a research-driven startup into a global leader in natural medicine, with clinically validated products adopted by top medical institutions.Now, at Eliaz Therapeutics, I’ve reunited with the key team members who d...","published_at":"2025-08-18T10:49:03Z","canonical_url":"https://wefunder.com/feed/184834"},{"id":184278,"entity_id":"wefunder:feed_item:184278","title":"This Changes Everything for Investors","preview":"To our valued Wefunder community,I’ve had a couple of weeks now to reflect on my trip to the 15th ISFA World Congress in Bangkok, and I’m still feeling the energy from the event. The theme was “Apheresis for Tomorrow,” and being there truly felt like we were stepping directly into that future.Over the course of countless conversations with many of the world’s leading minds in apheresis, I witnessed an undeniable sense of urgency to move beyond older, less selective methods. What became profou...","published_at":"2025-07-31T20:07:07Z","canonical_url":"https://wefunder.com/feed/184278"},{"id":184178,"entity_id":"wefunder:feed_item:184178","title":"MAJOR MILESTONE - FIRST PATIENT ENROLLED IN DIAGNOSTIC TRIALS","preview":"Dear Eliaz Therapeutics followers \u0026 investor,I am deeply humbled to announce that we’ve officially enrolled the first patient in our diagnostic clinical study at Tel Aviv Sourasky (Ichilov) Medical Center, a hospital ranked among the world's very best.This means that for the first time ever, we will systematically monitor the real-time level of Galectin-3 in critically ill sepsis patients during their ICU stay. By tracking these Galectin-3 dynamics, we aim to uncover the precise patterns that...","published_at":"2025-07-28T21:55:55Z","canonical_url":"https://wefunder.com/feed/184178"},{"id":184095,"entity_id":"wefunder:feed_item:184095","title":"Washington is Mobilizing Against Sepsis. But is it Enough?","preview":"Dear friends,Last month, the U.S. Senate reintroduced the bipartisan SEPSIS Act1 to funnel national resources toward better care and data collection. This comes at a critical time in our fight against sepsis as new federal data shows a nearly 40% increase2 in sepsis hospitalizations between 2016 and 2021.\u0026nbsp;This national spotlight is a significant step forward. But, as a physician who has watched families and patients fight what is often a lonely battle against an extremely deadly conditio...","published_at":"2025-07-24T20:57:37Z","canonical_url":"https://wefunder.com/feed/184095"},{"id":183843,"entity_id":"wefunder:feed_item:183843","title":"Your Investment on the Global Stage","preview":"To our valued Wefunder community,\u0026nbsp;Earlier this week, we shared our commitment to addressing the global sepsis crisis where it hits hardest.\u0026nbsp;Today, I am writing to you from the front lines of that mission at the 15th International Society for Apheresis World Congress in Bangkok, the world’s leading forum for apheresis science and clinical application.This event brings together:Top physicians and intensivists treating critically ill patients worldwideRenowned researchers advancing ext...","published_at":"2025-07-17T10:52:07Z","canonical_url":"https://wefunder.com/feed/183843"},{"id":183474,"entity_id":"wefunder:feed_item:183474","title":"Will you take one more step and help us share this mission?","preview":"Dear friends,Right now, we’re building something that could finally change the outcome of one of the deadliest medical emergencies on the planet: sepsis. Looking ahead, your support brings XGal-3® one step closer to reaching the patients who need it most. \u0026nbsp; ♥️ Click here to share our Wefunder campaign That single action helps us stand against a crisis that claims millions of lives. It empowers our work to bring XGal-3® to market, offering a future where sepsis is no longer a death senten...","published_at":"2025-07-07T12:00:53Z","canonical_url":"https://wefunder.com/feed/183474"},{"id":183434,"entity_id":"wefunder:feed_item:183434","title":"Why are Top Scientists Suddenly Adopting Our 30-Year-Old Strategy?","preview":"Dear friends,For decades, a truly effective treatment for sepsis was out of reach.\u0026nbsp;As a physician, I’ve seen firsthand how broad, non-specific therapies often failed to stop the runaway inflammation that makes sepsis so deadly. It gives me great hope to finally see a fundamental shift is happening in sepsis research, one that places our mission at the forefront of modern medicine.\u0026nbsp;A wave of new scientific research confirms the future of sepsis care lies in a new direction.\u0026nbsp;The ...","published_at":"2025-07-03T13:57:36Z","canonical_url":"https://wefunder.com/feed/183434"}],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-15T10:31:54Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-15T05:01:22Z","as_of":"2026-06-15T10:31:54Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-15T05:01:22Z","as_of":"2026-06-15T10:31:54Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-06-05T18:35:42Z","as_of":"2026-06-15T10:31:54Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-06-05T18:35:42Z","as_of":"2026-06-15T10:31:54Z","confidence":"medium"}}}}}}